In an open-label, single-arm, phase 2 trial, patients with advanced GC were given 20 mg of lenvatinib (significantly reduces TAMs and increases CD8+ T-cell infiltration) orally daily and 200 mg of pembrolizumab intravenously every 3 weeks until disease progression, intolerable toxicity, or withdrawal of consent (21). Here, CD8A is linked to gastric cancer.